Quick Answer
RenovoRx, Inc. reported Stockholders Equity of $5.42 million for the year ending 2025.
- RenovoRx, Inc. showed an increase of +21.1% in Stockholders Equity from 2024 to 2025.
- This data is from RenovoRx, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$11.94 million | Q2 2020: -$12.70 million | Q3 2020: -$13.79 million | Q1 2021: -$15.76 million | Q2 2021: -$17.06 million | Q3 2021: $17.55 million | Q1 2022: $12.54 million | Q2 2022: $10.12 million | Q3 2022: $8.15 million | Q1 2023: $3.26 million | Q2 2023: $1.19 million | Q3 2023: $6.0 thousand | Q1 2024: $1.77 million | Q2 2024: $9.27 million | Q3 2024: $7.07 million | Q1 2025: $13.16 million | Q2 2025: $10.64 million | Q3 2025: $8.08 million.
- Over the full 7 years of available data (2019 to 2025), RenovoRx, Inc.'s Stockholders Equity has grown by 149.6%.
- Historical annual values: Fiscal year 2025: $5.42 million | Fiscal year 2024: $4.48 million | Fiscal year 2023: $3.00 million | Fiscal year 2022: $6.16 million | Fiscal year 2021: $15.35 million | Fiscal year 2020: -$14.66 million | Fiscal year 2019: -$10.93 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: